Company Overview
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutics designed to treat fibrotic and inflammatory diseases within the United States market. The company functions within the broader healthcare sector, specifically inside the biotechnology industry, which implies a focus on high-risk, high-reward research and development phases rather than established commercial product sales. Chemomab Therapeutics Ltd. currently possesses a market capitalization of $10.51M, while its annual revenue and employee count are not disclosed in the available financial data. This limited market capitalization combined with the absence of reported revenue figures indicates that the company is in an early-stage development phase, where value is derived primarily from intellectual property and pipeline potential rather than current profitability or operational scale.
Financial Health
The company reports a net income of $-8,995,000 and an EBITDA of $-9,497,000 for the trailing twelve months, with revenue figures not available in the provided dataset. The significant gap between the reported net income and EBITDA, both of which are negative, reveals a cost structure dominated by substantial operating expenses typical of clinical-stage entities, where research and development costs heavily outweigh any current revenue generation. Chemomab Therapeutics Ltd. generated free cash flow of $-8,199,375, indicating a continuous burn rate that consumes available liquidity and limits immediate financial flexibility for expansion without further capital infusion. All three key margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, which signifies that the company has not yet achieved commercial revenue streams necessary to generate positive margins at this stage of development. The company holds cash reserves of $10.37M while holding no reported debt, resulting in a debt-to-equity ratio that is not applicable due to the lack of debt data. This balance sheet structure is highly conservative, as the absence of debt eliminates interest obligations and reduces financial risk associated with leverage. Furthermore, the current ratio stands at 9.08, which suggests an exceptionally strong short-term liquidity position capable of covering current liabilities many times over. Return on Equity is calculated at -69.5% and Return on Assets is -38.9%, metrics that reflect the dilutive impact of losses on shareholder equity and asset base rather than management effectiveness in generating profits.
Valuation Assessment
The trailing twelve-month P/E ratio is not applicable due to the lack of earnings, whereas the forward P/E ratio is listed at -48.67, a figure that reflects negative expected earnings rather than a traditional valuation multiple. The price-to-book ratio is 0.85, indicating that the market values the company at a discount relative to its net asset value, a common characteristic for biotechnology firms with significant intangible assets not fully captured on the balance sheet. Since revenue is not available, the price-to-sales ratio is not applicable, and the EV/EBITDA stands at -87.36, which serves as an alternative valuation metric highlighting the negative earnings multiple associated with the company's pre-revenue status. The 52-week high is $5.88 and the 52-week low is $1.35, placing the current trading range within a wide band of volatility typical for small-cap biotechnology stocks. The beta value is 0.54, meaning the stock exhibits lower price volatility relative to the broader market and is less sensitive to general market fluctuations compared to high-beta equities.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are not available in the provided facts, preventing a direct comparison of earnings expansion relative to revenue growth rates. As the company does not pay a dividend, the dividend yield is not applicable and the payout ratio is 0.0%, confirming that all available earnings and cash flow are retained within the company to fund ongoing research and development activities. Consequently, the company reinvests its limited financial resources entirely into growth initiatives rather than distributing income to shareholders, a standard strategy for clinical-stage biotechnology firms seeking to advance their product pipeline. The overall growth and income profile is characterized by a complete absence of current income generation and reliance on retained cash reserves to sustain operations until commercialization milestones are achieved.